Current status and reflections on immunotherapy and targeted therapy for unresectable biliary tract cancer
Biliary tract cancer (BTC) represents a group of highly malignant solid tumors with a five-year survival rate of only 10%. For patients with unresectable BTC, gemcitabine combined with cisplatin has been the conventional first-line treatment regimen. With the remarkable efficacy of immunotherapy and...
I tiakina i:
| Kaituhi matua: | |
|---|---|
| Hōputu: | Artigo |
| Reo: | Chinês |
| I whakaputaina: |
Editorial Office of Journal of Surgery Concepts & Practice
2025-11-01
|
| Rangatū: | Waike lilun yu shijian |
| Ngā marau: | |
| Urunga tuihono: | https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1769412719033-58656474.pdf |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|